Ketamine can produce a temporary state that closely mimics psychosis, with hallucinations, paranoid thinking, and disordered thought ranking among the most prominent features. In controlled studies, hallucinations are the single most common positive symptom after a ketamine infusion, outstripping delusions and other psychotic experiences. For most people, these effects fade within an hour or two, but chronic heavy use can push a small subset of users into a persistent psychotic state that resembles schizophrenia in structure, if not always in severity. Understanding the full picture means looking at what happens during acute exposure, what changes with repeated use, and why some people are more vulnerable than others.
What Acute Ketamine Psychosis Looks and Feels Like
Researchers have mapped the symptom profile of ketamine-induced psychosis fairly precisely, largely because ketamine has been used in controlled laboratory settings as a pharmacological model for schizophrenia. In these studies, healthy volunteers receive a subanesthetic dose of ketamine by infusion while clinicians rate their symptoms on standardized psychiatric scales. A systematic review and meta-analysis covering these trials found that positive psychotic symptoms (the kind involving distortions of reality rather than blunted emotion) rose sharply compared to placebo, with a large effect size.1JAMA Network Open. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis
Among those positive symptoms, hallucinations dominate. One study that broke down individual symptom categories found that hallucination scores exceeded those for delusions, conceptual disorganization, hostility, persecution, grandiosity, and unusual thought content.2PubMed Central. Ketamine-Induced Hallucinations The hallucinations tend to be visual and perceptual rather than auditory, which is one way the acute ketamine experience often differs from the hallucinations reported in schizophrenia. People commonly describe vivid distortions of shape, color, and spatial orientation, a sense of objects melting or morphing, and sometimes full immersive scenes that feel dream-like. Body perception changes dramatically too: users frequently report feeling detached from their limbs, floating, or dissolving entirely.
Alongside hallucinations, ketamine reliably produces negative symptoms (emotional flattening, social withdrawal, reduced speech) and general symptoms like confusion, difficulty concentrating, and a sense that thoughts are scrambled. In the controlled studies, general symptoms were actually the most elevated category overall, meaning that the cognitive fog and disorientation were even more prominent than the hallucinations themselves, though the hallucinations were the standout feature among the specifically psychotic symptoms.2PubMed Central. Ketamine-Induced Hallucinations
How the Experience Differs for People With Schizophrenia
The symptom picture shifts in an important way when ketamine is given to people who already have a psychotic disorder. In a study comparing responses in healthy volunteers and people with schizophrenia, both groups experienced worsening positive and negative symptoms, but the qualitative character of those symptoms diverged. People with schizophrenia developed auditory hallucinations and paranoia, while the healthy volunteers largely did not.3PubMed. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics The patients also experienced further drops in recall and recognition memory beyond their already impaired baseline.
This distinction matters practically. The psychotic symptoms ketamine triggers in someone without a history of psychosis tend to be recognizably “trippy” even to the person experiencing them. There is often some degree of awareness that the perceptual disturbances are drug-induced. But for someone already prone to psychosis, ketamine can tip the experience into something that feels indistinguishable from a genuine psychotic episode, with the person losing insight into what is real. That loss of insight is a major clinical concern, because it makes the episode harder to manage and potentially more traumatic.
Why Ketamine Produces Psychotic Symptoms
The primary mechanism involves a receptor in the brain called the NMDA receptor, which plays a central role in how nerve cells communicate using the signaling molecule glutamate. Ketamine blocks this receptor. The block is not uniform across all brain cells, though. Research has focused on the possibility that ketamine preferentially disrupts the function of a specific type of neuron, the inhibitory interneurons, which normally act as brakes on excitatory activity in the brain.4PubMed Central. Ketamine: NMDA Receptors and Beyond When those brakes are weakened, the net result is a paradoxical increase in excitatory glutamate signaling in parts of the cortex, which can produce the perceptual chaos and disordered thinking that characterize psychosis.
This glutamate disruption also triggers changes downstream in the dopamine system, the neurotransmitter system most traditionally associated with psychosis. A meta-analysis of animal studies found that acute ketamine increases dopamine levels in the striatum, the nucleus accumbens, and the frontal cortex, with medium to very large effect sizes depending on the brain region.5Molecular Psychiatry. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders In humans, ketamine pretreatment has been shown to amplify the dopamine release triggered by amphetamine, suggesting it loosens the regulatory controls on dopamine signaling in the striatum.6PubMed. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia
The dopamine piece is particularly relevant because excess dopamine activity in certain brain circuits is the leading explanation for positive psychotic symptoms like hallucinations and delusions in schizophrenia. With repeated ketamine exposure, this effect gets worse. Animal research has shown that sub-chronic ketamine treatment significantly increased the brain’s capacity to produce dopamine in the striatum, with a very large effect, and this was accompanied by behavioral sensitization (increasing hyperactivity with repeated doses) that persisted even after a washout period.7PubMed Central. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine In other words, the dopamine system does not simply bounce back to normal between doses. Repeated use appears to re-calibrate it in a way that mirrors what is seen in schizophrenia.
How Ketamine Connectivity Changes Mirror Schizophrenia
Beyond the chemical signaling, ketamine also disrupts how brain networks talk to each other. Researchers using brain imaging have found that ketamine alters resting-state functional connectivity in patterns that overlap with those seen in schizophrenia, particularly in connections involving the thalamus and the cortex.8PubMed Central. Reviewing the ketamine model for schizophrenia The thalamus acts as a relay station that filters sensory information before it reaches higher brain areas. When that filter malfunctions, the brain gets flooded with unprocessed sensory data, which may contribute to hallucinations and the feeling that reality is overwhelming or incomprehensible.
The overlap is not perfect, which is scientifically informative in its own right. A multicenter imaging study found that while ketamine reproduced some connectivity signatures seen in schizophrenia, other patterns looked more like what researchers see in the early stages of the illness, and a few schizophrenia-associated connectivity changes were not recreated by ketamine at all. This suggests that ketamine captures an important piece of the schizophrenia puzzle but not the whole thing, which is one reason researchers continue to use it as a model for the disorder while acknowledging its limitations.
When Psychosis Persists After Chronic Use
For occasional or one-time users, the psychotic symptoms wear off as the drug clears the system, usually within a couple of hours. The more concerning scenario involves people who use ketamine heavily and repeatedly over months or years. In this population, a subset develops persistent psychosis that continues even during periods of abstinence.
A study of young recreational users who took ketamine multiple times a week found a significant positive correlation between frequency of use and psychotic-like experiences, even after accounting for other substance use.9PubMed. Psychotic-Like Experiences in Young Recreational Users of Ketamine: A Case Study Research into chronic ketamine-dependent patients has confirmed that the psychotic symptoms and cognitive impairments in those with persistent psychosis bear clear resemblances to schizophrenia, though they are often somewhat less severe in users without persistent psychosis.10PubMed. Ketamine-dependent patients with persistent psychosis have higher neurofilament light chain levels than patients with schizophrenia
Interestingly, in a study profiling chronic ketamine users more broadly, the vast majority (about 92%) had psychotic symptoms that fell below the threshold for even mild illness on a standard rating scale. Only about 8% scored in the mild range, and none reached moderate or severe levels of schizophrenia-like symptoms.11PubMed Central. Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users What stood out instead was that depression was far more common and severe in these chronic users. About three-quarters had depressive symptoms in the moderate to severe range, and roughly a third reported moderate anxiety. So while ketamine psychosis grabs attention, the everyday psychiatric toll of chronic ketamine use leans more toward depression and anxiety than full-blown psychotic disorders for most users.
What Happens to the Brain With Long-Term Use
Long-term heavy ketamine use leaves structural fingerprints on the brain. A systematic review of neuroimaging studies found that chronic recreational ketamine use was associated with lower gray matter volume, reduced white matter integrity, and weaker functional connectivity between the thalamus and cortex as well as between cortical regions.12PubMed Central. Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review These structural and connectivity changes help explain the cognitive and psychiatric side effects reported by long-term users, including memory problems and difficulties with executive functioning.
The damage is not evenly distributed. Longer duration of ketamine use has been linked to more extensive thinning of the cortex, particularly in areas involved in memory (the parahippocampal gyrus) and higher-order thinking (frontal, parietal, and occipital cortex).13Frontiers in Neuroanatomy. Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review – Section: Results A separate imaging study found significant decreases in gray matter specifically in the frontal cortex of ketamine users compared to controls, and the longer someone had been using, the more pronounced the loss.14PubMed. Reduced dorsal prefrontal gray matter after chronic ketamine use The frontal cortex is critical for judgment, planning, impulse control, and reality testing, which are exactly the cognitive domains that deteriorate most visibly in chronic users.
Age, Cannabis, and Other Vulnerability Factors
Not everyone who takes ketamine develops psychotic symptoms to the same degree, and the research points to several factors that increase vulnerability. The most important is probably age at exposure. Animal research has found that ketamine exposure during the brain’s developmental window (roughly equivalent to adolescence in humans) causes delayed-onset disruptions in brain electrical activity that do not appear until adulthood. Specifically, juvenile exposure led to later impairments in gamma oscillations and event-related brain potentials, suggesting that the drug interrupted normal neural maturation in ways that only became apparent later.15PubMed Central. Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice This finding is concerning because recreational ketamine use skews young, and a developing brain may be especially susceptible to lasting disruption of the glutamate and dopamine systems.
Pre-existing psychotic illness is another clear risk factor. As noted in the earlier comparison between healthy volunteers and people with schizophrenia, the latter group experienced qualitatively worse and more clinically relevant psychotic symptoms, including the type of auditory hallucinations characteristic of their illness.3PubMed. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics A family history of psychotic disorders, even in someone who has never experienced psychosis themselves, is also treated as a risk factor in clinical settings, though the research base for this specific claim in the context of ketamine is thinner.
Concurrent cannabis use has also drawn attention. A published case report described persistent psychosis following intravenous ketamine in a patient who was also using cannabis, prompting a literature review exploring the interaction.16PubMed. Persistent Psychosis Associated With Intravenous Ketamine in a Patient Using Cannabis: A Case Report and Literature Review Cannabis alone is associated with an increased risk of psychotic experiences, and when layered on top of ketamine’s glutamate and dopamine disruption, the combination may heighten the probability of a psychotic episode that outlasts the acute intoxication. The evidence here is still mostly at the case-report level, but the biological plausibility is strong enough that clinicians tend to view the combination with extra caution.
Treatment When Psychosis Develops
For acute ketamine-induced psychotic episodes, time is usually the primary treatment. Because ketamine’s half-life is relatively short, most psychotic symptoms resolve on their own within an hour or two as the drug is metabolized. In emergency or clinical settings, management typically involves keeping the person in a safe, low-stimulation environment and providing reassurance. Benzodiazepines may be used to manage agitation or extreme distress.
When psychosis persists beyond the window of acute intoxication, antipsychotic medication becomes relevant. Case reports have documented successful treatment of ketamine-induced persistent psychosis with antipsychotic drugs. One case study specifically described a complete resolution of the clinical picture using paliperidone, a second-generation antipsychotic.17PubMed. Paliperidone for the treatment of ketamine-induced psychosis: a case report Given that the dopaminergic hyperactivity produced by ketamine overlaps with the dopamine dysfunction targeted by antipsychotics, the pharmacological rationale for using these medications in this context is fairly straightforward. That said, evidence for any particular antipsychotic being “best” for ketamine psychosis comes from case reports and small series rather than controlled trials, so treatment decisions remain partly empirical.
Abstinence from ketamine is the most critical component of treatment for chronic users experiencing persistent psychosis. Research has shown that cognitive functioning in chronic ketamine users improves meaningfully after 12 weeks of abstinence, with gains in verbal and visual memory and executive function.18PubMed. Recovery of cognitive functioning following abstinence from ketamine Whether psychotic symptoms follow the same recovery trajectory depends on severity and duration, but the cognitive recovery data are encouraging and suggest that some of the brain changes are at least partially reversible with sustained abstinence.
Ketamine Therapy for Depression and Psychosis Risk
The growing clinical use of ketamine and its close relative esketamine (marketed as Spravato) for treatment-resistant depression raises natural questions about psychosis risk in a medical context. The doses used therapeutically are subanesthetic, meaning they are much lower than those typically used recreationally to reach dissociative or psychotic states. In clinical settings, patients are monitored for dissociative symptoms, perceptual changes, and elevations in blood pressure during and after each session.
Transient perceptual disturbances do occur during therapeutic ketamine infusions, including mild visual distortions, a sense of unreality, and sometimes fleeting paranoid thoughts. These are generally considered expected side effects rather than signs of a developing psychotic disorder, and they resolve within the monitoring window. Most treatment protocols list a personal or family history of psychotic disorders as a relative or absolute contraindication, precisely because of the evidence discussed earlier that such individuals are more susceptible to severe psychotomimetic effects.
The key distinction is between the transient, dose-dependent psychotic symptoms that are part of the drug’s acute pharmacology and the persistent psychotic states that emerge with chronic, heavy, uncontrolled use. There is no strong evidence that a standard course of therapeutic ketamine, administered at controlled doses under medical supervision, triggers lasting psychosis in people without pre-existing vulnerability. But the evidence base is still maturing, and long-term follow-up data from large clinical populations are limited. Clinicians screening patients for ketamine therapy typically ask about personal and family psychiatric history, current substance use, and any prior adverse reactions to dissociative agents.
The Developing Brain and Delayed Effects
One of the more unsettling findings in the ketamine literature involves the possibility that exposure during adolescence can cause brain abnormalities that surface only years later. The animal research showing delayed-onset disruption of brain oscillations following juvenile ketamine exposure raises a question that cannot yet be answered in humans: are teenagers who use ketamine recreationally at risk for psychiatric problems that will not manifest until their twenties or later?15PubMed Central. Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice
The researchers who conducted this work pointed out that the delayed onset of impairment opens a potential window for detection and intervention, meaning that if clinicians knew what early biomarkers to look for, they might be able to identify and treat the effects of adolescent ketamine exposure before overt psychiatric symptoms develop. This is speculative at this stage, but it highlights a concern that goes beyond the immediate question of “what will happen to me tonight if I take ketamine.” For young people using the drug regularly, the more important question may be about what their brains will look like in five or ten years. The cortical thinning and connectivity changes seen in adult chronic users, particularly in the frontal cortex, could be even more consequential when they occur during a period of active brain development.